53 results about "Drug crystals" patented technology

The invention discloses a low-water-solubility medicine crystal as well as a preparation method and application thereof. The compound Z pamoate crystal form I has large characteristic diffraction peaks at one or more positions with diffraction angles 2 theta of 9.9 + / -0.2 degrees, 10.7 + / -0.2 degrees, 12.1 + / -0.2 degrees, 14.9 + / -0.2 degrees, 17.3 + / -0.2 degrees, 19.4 + / -0.2 degrees, 20.7 + / -0.2 degrees and 23.1 + / -0.2 degrees. Compared with an amorphous compound Z pamoate, the crystal provided by the invention has the advantages of good stability, no crystal transformation phenomenon, no obvious increase of related substances and low solubility; the production process is simple, only water is used as a solvent in the whole process, and no organic solvent is used; when the long-acting slow-release anti-Parkinson medicine composition is prepared from the compound Z pamoate crystal form I, the medicine encapsulation efficiency is high, the burst release is low, the composition continuously releases the medicine in vivo for more than 2 weeks, the administration frequency of a patient can be reduced, and the medication compliance is improved.

The invention relates to the technical field of intelligent drug crystal form analysis, in particular to an intelligent drug crystal form analysis system based on model driving, which comprises a Raman scattering chart construction module, an intelligent crystal form characteristic peak analysis module and an intelligent crystal form identification closed-loop verification module, and is characterized in that the Raman scattering chart construction module is used for constructing a Raman spectrum chart; the crystal form characteristic peak intelligent analysis module judges whether the characteristic peak is a crystal form characteristic peak or not, and defines a crystal form characteristic pattern; peak position and peak intensity weight coefficients are set, comprehensive matching degrees are calculated in sequence, and drug crystal forms of characteristic peaks in the crystal form characteristic pattern are judged; the crystal form intelligent identification closed-loop verification module is used for establishing a crystal form analysis model, judging the crystal form type when the crystal form of the medicine cannot be identified, adjusting a method for judging a crystal form characteristic peak in the crystal form characteristic peak intelligent analysis module, adjusting a peak position and a peak strength weight coefficient according to the crystal form type, and calculating the comprehensive matching degree of the medicine again; and if the crystal form of the medicine still cannot be identified, outputting an unrecognizable signal.

The invention provides a drug crystal target detection tracking method based on YOLO-SAM2, and the method comprises the steps: optimizing a YOLO11 model, employing an improved feature pyramid network (SOEP), enabling a P2 feature layer of the model to pass through space-to-depth convolution SPD-Conv, obtaining features rich in small target information, and feeding the features to P3 for fusion, feature integration is carried out by using a cross-stage local CSP thought and a CSP-OKM obtained by improving an all-round convolution module OKM, so that the small target detection performance of the model is improved; and meanwhile, crystal target detection is carried out by utilizing the improved YOLO11-SOEP, and the obtained bounding box prediction is used as prompt input of the SAM2 model to track crystal growth and obtain a segmentation mask of the whole crystallization process so as to analyze the crystal growth. According to the method, the medicine crystal type can be recognized, the segmentation effect is remarkable, the requirement for manual intervention is reduced, the automation degree and accuracy of data analysis are improved, and the practical value is high.

The invention belongs to the technical field of medicine crystals, and relates to cordycepin-oxalate as well as a preparation method and application thereof. The invention relates to a preparation method of cordycepin-oxalate. The preparation method comprises the following steps: (1) physical mixing: sufficiently and uniformly mixing oxalic acid and cordycepin-crystal form II crystals; (2) liquid auxiliary grinding: adding an auxiliary agent, and continuously grinding to obtain a solid mixture; and (3) drying the solid mixture to obtain the cordycepin-oxalate. According to the method, the cordycepin-oxalic acid eutectic salt is prepared for the first time, the dissolution rate of the cordycepin-oxalic acid eutectic salt is obviously lower than the dissolution rate of cordycepin reported in the prior art, and the cordycepin-oxalic acid eutectic salt has extremely high potential medicinal application value. The cordycepin-oxalic acid eutectic salt has important technical innovation and market application potential due to the slow release effect.

The invention relates to the field of medicine crystal forms, in particular to a chidamide crystal form I and a preparation method thereof. The chidamide crystal form I has better stability, flowability and solubility, good bioavailability and lower hygroscopicity, has the advantage of patent medicine, and can be developed as a medicinal crystal form; the preparation method of the crystal form I is simple, good in repeatability, high in yield, easy to operate, green, environmentally friendly, small in needed solvent amount and beneficial to recycling, the reagent cost can be effectively reduced, and large-scale production is easy to achieve.

The application discloses a baicalin ternary co-amorphous drug and a preparation method and application thereof, and the amorphous substance can effectively improve the solubility and dissolution of puerarin and baicalin. The application mixes metformin hydrochloride, puerarin and baicalin according to a molar ratio of 1:1:1, and obtains the baicalin ternary co-amorphous drug through a ball milling method or a solvent-assisted milling method, the preparation method is green and efficient, the co-amorphous substance has high light stability and thermal stability, the solubility is increased by 1.7 times compared with that of a puerarin raw drug crystal, the solubility is increased by 46.8 times compared with that of a baicalin raw drug crystal, and the solubility is reduced by 14.8 times compared with that of a metformin hydrochloride raw drug crystal. The baicalin ternary co-amorphous drug has certain application prospects in liver protection, blood sugar reduction, treatment of damp-heat type colitis and cervical cancer.

The present invention relates to a coating material for drug-coated balloons, drug-coated balloons, and a coating solution for drug-coated balloons, as well as their preparation and application. The coating solution comprises an aqueous solvent and a plurality of core-shell structures dispersed in the aqueous solvent, each of which comprises a lipid bilayer coated with a drug. The core of the core-shell structure contains a plurality of drug-loaded particles, and the shell of the core-shell structure is a lipid bilayer with an outer hydrophilic group and an inner hydrophobic group. The drug-loaded particles comprise a plurality of drug-loaded nanocrystalline particles. The combination of nanocrystals and liposomes combines the advantages of these two types of drug carriers. The resulting lipid bilayer improves the solubility of poorly soluble drugs in drug-coated balloons, resulting in a high drug loading capacity, high drug carrier stability, and stable drug crystal form, allowing for controllable drug release rates.

The invention belongs to the field of drug delivery, and particularly relates to a glucose and ketone body dual-response long-acting insulin delivery system as well as a preparation method and application thereof. The glucose and ketone body dual-response long-acting insulin delivery system provided by the invention comprises a drug crystal, a polymer coating wrapping the drug crystal and a phenylboronic acid based cationic polymer modified in the polymer coating. The long-acting insulin can prolong the treatment time of the glucose-responsive insulin delivery carrier, meanwhile, the glucose-responsive insulin delivery carrier has a ketone body response behavior, ketoacidosis is inhibited, and the problems that an existing glucose-responsive insulin delivery carrier is short in treatment time, a ketone body-responsive insulin delivery carrier is difficult to construct and the like are solved.

The present application relates to the technical field of drug crystal form intelligent analysis, in particular to a drug crystal form intelligent analysis system based on model driving, which comprises a Raman scattering diagram construction module, a crystal form characteristic peak intelligent analysis module and a crystal form intelligent recognition closed loop verification module, wherein: the Raman scattering diagram construction module is used for constructing a Raman spectrum diagram; the crystal form characteristic peak intelligent analysis module is used for judging whether a characteristic peak is a crystal form characteristic peak, defining a crystal form characteristic diagram, setting a peak position and a peak intensity weight coefficient, sequentially calculating a comprehensive matching degree, and determining a drug crystal form of the characteristic peak in the crystal form characteristic diagram; and the crystal form intelligent recognition closed loop verification module is used for establishing a crystal form analysis model, judging a crystal form type when a drug crystal form cannot be recognized, adjusting a method for judging a crystal form characteristic peak in the crystal form characteristic peak intelligent analysis module, adjusting the peak position and the peak intensity weight coefficient according to the crystal form type, and again calculating a drug comprehensive matching degree; if the drug crystal form still cannot be recognized, an unrecognizable signal is output.

The invention discloses a menbutone sodium polymorph and a preparation method and application thereof, and belongs to the technical field of medicine crystal forms. The menbutone sodium polymorph comprises a menbutone sodium crystal form A, a menbutone sodium crystal form B and a menbutone sodium crystal form C. The menbutone sodium has the following structural formula: the brand-new menbutone sodium polymorph provided by the invention has good solubility and dissolution rate, has better mixing performance in a powder preparation process, has excellent preparation processability, and can be used for preparing the menbutone sodium crystal form. The crystal purity is high; the storage stability is good. The crystallization method of the crystal form A, the crystal form B and the crystal form C of the menbutone sodium provided by the invention has a good removal effect on a specific impurity A in the menbutone, and is simple in process, easy to operate and suitable for industrial production.

Provided is a balloon catheter with which a drug transferred from a balloon to a blood vessel wall does not easily separate from the blood vessel wall.　This balloon catheter has a balloon (20). The balloon (20) has a balloon body part (30) having a longitudinal direction x and a radial direction y, and a drug layer (40) that is disposed outward of the balloon body part (30) in the radial direction y and contains a drug. The drug layer (40) has a radial crystal group (42) including a plurality of columnar crystals (41) of the drug arranged radially. In a cross section in the longitudinal direction x, the radial crystal group (42) has a fan shape, and the central angle θ of the fan shape exceeds 180°.

The invention relates to a rapid identification method for a crystal form of a complex mixture conjugated estrogen drug obtained by separation and purification of a natural pregnant mare urine source, and adopts a scanning electron microscope-confocal microscopy ramann coupling technology to determine a natural conjugated estrogen bulk drug and a preparation thereof. And carrying out difference analysis with conjugated estrogen from a synthesis source. According to the detection method, a microscopic area is positioned through a scanning electron microscope, fixed-point chemical analysis is performed through confocal microscopic Raman, the corresponding relation between morphology and crystal form is revealed, and the method is high in spatial resolution (micron level), high in specificity and good in reproducibility. Therefore, the method can be used for simply, quickly and accurately detecting the characteristic peak of the sample to be detected, reveals the special molecular arrangement mode and crystal structure characteristics of the conjugated estrogen drug produced by a specific process, and has a very good application prospect in the field of crystal form quality control of the drug.

The invention relates to the technical field of medicine crystal forms, and particularly discloses a novel crystal form of an AXL kinase inhibitor, a dextro-camphorsulfonate crystal form I and a dextro-camphorsulfonate crystal form II are prepared, and the dextro-camphorsulfonate crystal form I and the dextro-camphorsulfonate crystal form II are both anhydrides and have good physical stability and chemical stability. After the camphor sulfonate crystal form I and the camphor sulfonate crystal form II are placed under the conditions of high temperature (60 DEG C), high humidity (92.5% RH) and illumination for 10 days, the appearance of the camphor sulfonate crystal form II has no obvious change and has no obvious difference in 0 day, and compared with the camphor sulfonate crystal form I and the camphor sulfonate crystal form II, the camphor sulfonate crystal form II is more stable in thermodynamic stability tests in ethanol and methanol supersaturated solutions.

A pharmaceutical crystal having low water solubility, a preparation method therefor, and the use thereof. A crystal form I of pamoate of a compound Z has characteristic diffraction peaks at the diffraction angles 2θ of 9.9±0.2°, 10.7±0.2°, 12.1±0.2°, 14.9±0.2°, 17.3±0.2°, 19.4±0.2°, 20.7±0.2° and 23.1±0.2°. Compared with amorphous pamoate of the compound Z, said crystal has good stability, is free of polymorphic transformation, does not involve obvious increases of related substances, and has a low solubility. A production process therefor is simple and only uses water as a solvent in the whole process without the need of using an organic solvent. Using the crystal form I of pamoate of the compound Z for preparing a long-acting sustained-releasing pharmaceutical composition for Parkinson's disease can achieve a high drug encapsulation ratio and low burst release, and enables drug release of the composition in vivo to last for over two weeks, so that the frequency of drug administration to patients can be reduced, and the medication compliance is improved.

The utility model relates to the field of plant area sweeping, and discloses a cement plant area medicament adding area sweeping system which comprises a sweeping device, supporting rollers are symmetrically arranged on the edge of one side of the sweeping device, a supporting holding rod is fixedly installed on one side of the upper surface of the sweeping device, and guide supporting rods are symmetrically welded to the two sides of the inner wall of the sweeping device. A movable support is movably installed on the outer surface of the guide supporting rod in the sweeping device, the bottom end of the movable support extends to the position below the sweeping device to be provided with a sweeping brush head, a fixed sliding groove is formed in one side of the inner wall of the sweeping device, and the middle of one side of the movable support penetrates through the fixed sliding groove to be fixedly connected with a connector. According to the cleaning device, the cleaning brush head is adjusted to reciprocate along the lower portion of the cleaning device, so that the effect of conveniently cleaning the drug crystals in the drug adding area is achieved, the cleanliness of the road surface in the drug adding area is improved, the problem that the drug crystals are bonded to the road surface and are inconvenient to clean is solved, and the overall cleaning efficiency of the drug crystals is improved.

The application relates to a microfluidic chip with a substrate surface functional modification and a crystallization control method, which solves the technical problem of how to apply the microfluidic chip to precisely control the crystallization process, and comprises a substrate and a cover plate, the substrate is provided with patterned SAMs, the cover plate comprises an upper layer and a lower layer, the upper layer is provided with a gas passage and a gas containing chamber, the upper layer is provided with a gas input through hole, a gas output through hole, a liquid input through hole and a liquid output through hole, the lower layer is provided with a liquid passage and a reaction chamber, the lower layer of the cover plate is bonded with the substrate, and the patterned SAMs are located in the reaction chamber. The application is suitable for precise preparation of drug crystals, biological materials, ceramic materials, nanometer materials and optical elements, and can be widely applied to the pharmaceutical industry, biomedical engineering, advanced material synthesis and other industries.

The invention relates to the field of medicines, and discloses a pharmaceutical composition for treating obstructive sleep apnea as well as a preparation method and application thereof. The pharmaceutical composition comprises a ternary co-amorphous compound containing zinc ions, and raw materials of the ternary co-amorphous compound comprise suthiamethoxam, L-arginine, a divalent zinc ion donor and a surface stabilizer. Wherein zinc ions form a cross-linked network with the suthiamethoxam and the L-arginine through coordination, so that drug lattices are destroyed, and molecular movement is limited. According to the preparation method, a liquid-assisted high-energy mechanical ball milling process is adopted, a trace amount of coordination catalytic liquid is added to reduce a solid-phase reaction energy barrier, and efficient conversion from a crystalline state to an amorphous state is realized. Through the synergistic effect of multiple components, the saturation solubility and the dissolution rate of the suthiamethoxam are remarkably improved, meanwhile, the coordination crosslinking of zinc ions and the steric hindrance effect of the surface stabilizer are utilized, crystal transformation of an amorphous system is effectively inhibited, and the physical stability and oral bioavailability of the medicine are enhanced.

The present disclosure includes methods for forming pharmaceutical crystals of narrow particle size distribution and desired size and morphology, including a recrystallization step and subsequent resizing step.

The present invention provides a drug balloon and a preparation method thereof, including: providing a balloon body; pretreating the surface of the balloon body with a target reagent to improve the cleanliness and roughness of the surface of the balloon body; performing seeding treatment on the surface of the pretreated balloon body with a dispersion liquid containing nano-drug particles and a dispersant, so as to attach nano-drug particles to the surface of the balloon body in a physically adsorbed manner to form a seed layer; performing crystal growth treatment on the surface of the balloon body with a supersaturated solution of the active pharmaceutical ingredient to grow drug crystals precipitated from the saturated solution on the seed layer, which can adsorb pure drugs on the balloon surface without using excipients, is not easy to fall off, and is convenient for eluting and transferring drugs.

This invention provides a sulfathiazole-trimethoprim drug crystal salt, its preparation method, and its application, belonging to the field of drug crystal salt technology. The sulfathiazole-trimethoprim drug crystal salt provided by this invention is orthorhombic with a space group of [space group missing]. P bca; cell parameters are: a =17.3213(3)Å, b =12.2894(2)Å, c =23.7549(3)Å, α =90°, β =90°, c =90°; wherein the molar ratio of sulfathiazole to trimethoprim is 1:1, and there is no crystallizing solvent. The sulfathiazole-trimethoprim drug crystal salt provided by this invention has high solubility in water, which is beneficial to improving absorption and metabolism in humans and animals, and has excellent antibacterial effect.

The invention relates to a substrate surface functionalization modified micro-fluidic chip and a crystallization control method, and solves the technical problem of how to use the micro-fluidic chip to accurately control the crystallization process, the substrate comprises a substrate and a cover plate, the substrate is provided with patterned SAMs, the cover plate comprises an upper layer and a lower layer, the upper layer is provided with a gas channel and a gas accommodating chamber, and the lower layer is provided with a gas outlet. The upper layer is provided with a gas input through hole, a gas output through hole, a liquid input through hole and a liquid output through hole, the lower layer is provided with a liquid channel and a reaction chamber, the lower layer of the cover plate is bonded with the substrate, and the patterned SAMs are located in the reaction chamber. The method is suitable for precise preparation of drug crystals, biological materials, ceramic materials, nanometer materials and optical elements, and can be widely applied to the industries of pharmacy, biomedical engineering, advanced material synthesis and the like.

The present application belongs to the field of chemical engineering and medicine manufacturing, and particularly relates to a method for regulating drug crystal form by oxidizing nanocellulose and application. By inducing the generation of sulfathiazole crystals in TCNF solutions with different concentrations, the nucleation and growth process of the sulfathiazole crystals is controlled, so that different morphologies and structures of the sulfathiazole crystal forms are obtained, and the transformation of the sulfathiazole crystals from flaky, prismatic to regular hexagonal crystal forms is realized. The sulfathiazole crystal form prepared by the method has better crystal morphology and consistency, the method is simple and effective, is suitable for crystal form optimization and large-scale production of polymorphic drugs, and has important industrial application value.

The present disclosure is directed toward composite materials comprising high aspect ratio habits of drug crystals which can be partially or fully extending into a substrate, and additionally, can be projecting from a substrate at an angle of about 20° to about 90°. The present disclosure is directed toward medical devices, such as medical balloons, comprising said composite and methods of using and making the same. The described composite can be used for the local treatment of vascular disease. The present disclosure is also directed toward paclitaxel crystals with a hollow acicular habit.

The invention provides a sulfathiazole-trimethoprim medicine crystal salt as well as a preparation method and application thereof, and belongs to the technical field of medicine crystal salts. The sulfathiazole-trimethoprim drug crystal salt provided by the invention is an orthorhombic crystal system, and the space group is Pbca; the cell parameters are as follows: a is equal to 17.3213 (3), b is equal to 12.2894 (2), c is equal to 23.7549 (3), alpha is equal to 90 degrees, beta is equal to 90 degrees, and gamma is equal to 90 degrees; wherein the molar ratio of sulfathiazole to trimethoprim is 1: 1, and no crystalline solvent exists. The sulfathiazole-trimethoprim drug crystal salt provided by the invention has high solubility in water, is beneficial to improvement of absorption and metabolism conditions in human bodies and animal bodies, and has an excellent antibacterial effect.

The present application belongs to the technical field of pharmaceutical crystal, and relates to a solid salt type, a crystal form of an opioid receptor antagonist conjugate and a preparation method, a composition and a use thereof. Specifically, the conjugate has a structure as shown in formula I, and can form a stably existing solid phosphate salt, wherein the molar ratio of phosphoric acid to the compound of formula I is 1:1-3:1. The phosphate salt can be an amorphous substance or a polymorph having crystal form 1, 2, 3 or 4, and the preparation method is simple and easy to operate, and is suitable for preventing and treating intestinal function disorders caused by opioid drugs, such as constipation.

The present invention belongs to the field of drug delivery, and specifically relates to a glucose and ketone body dual-response long-acting insulin delivery system, and a preparation method therefor and the use thereof. The glucose and ketone body dual-response long-acting insulin delivery system provided in the present invention comprises a drug crystal, a polymer coating encapsulating the drug crystal, and a phenylboronic-acid-based cationic polymer modified in the polymer coating. Long-acting insulin can prolong the treatment time of a glucose-responsive insulin delivery carrier and also has ketone body-responsive behavior, thereby inhibiting the occurrence of ketoacidosis. Therefore, problems such as the short treatment time of existing glucose-responsive insulin delivery carriers and the difficulty in constructing ketone body-responsive insulin delivery carriers are solved.

To develop pharmaceutical crystals suitable for formulation of a compound.SOLUTION: Polymorphic forms of a compound and a preparation method therefor and an application thereof are disclosed. A crystal form III of a compound A uses Cu-Kα radiation, and X-ray powder diffraction expressed at 2θ angles has characteristic peaks at 12.15±0.20°, 15.98±0.20°, 16.62±0.20°, 17.14±0.20°, 24.32±0.20°, and 26.08±0.20°. A crystal form VII of the compound A uses Cu-Kα radiation, and X-ray powder diffraction expressed at 2θ angles has characteristic peaks at 12.94±0.20°, 14.41±0.20°, 15.64±0.20°, 17.25±0.20°, 21.75±0.20°, and 24.23±0.20°. The polymorphic forms prepared by the present invention are good in stability, and can be stably stored under the conditions of high temperature and low relative humidity.SELECTED DRAWING: Figure 28

The application relates to the field of drug crystal forms, in particular to a new crystal form of a compound of formula I and a preparation method thereof. The crystal form II of the compound of formula I has the comprehensive advantages of good physical and chemical stability, low moisture absorption, good solubility and bioavailability, and thus has certain drug property and drug development value. In addition, the preparation method of the crystal form II of the compound of formula I is simple in steps, mild in conditions, good in process repeatability, high in purity and low in cost, and is suitable for industrial large-scale production.

The invention relates to the field of medicine crystal forms, in particular to an orselidine fumarate crystal form I. The obtained crystal form I has good physical stability and chemical stability, extremely low hygroscopicity and good solubility and can be developed as a raw material medicine, and the preparation process provided by the invention is simple, good in repeatability, excellent in purification effect and good in process amplification stability and can be used for industrial large-scale amplification production.

The application belongs to the technical field of pharmaceutical crystal, and relates to a crystalline form of nervonic acid and a preparation method thereof. In the X-ray powder diffraction pattern of the crystalline form, Cu-Kalpha radiation has characteristic peaks at diffraction angles 2theta of 5.2+ / -0.2, 8.8+ / -0.2, 12.4+ / -0.2, 16.0+ / -0.2, 19.2+ / -0.2, 23.9+ / -0.2 and 25.2+ / -0.2. The crystalline form provided by the application has good chemical purity and crystal stability, and exhibits excellent physical stability, which is beneficial to the development, production and storage of pharmaceutical preparations. In addition, research shows that the crystalline form also has suitable solubility characteristics, which is beneficial to improving the bioavailability and more beneficial to the related research and development of drugs.